Alisertib, a novel oral Aurora A kinase (AAK) inhibitor, has antitumor activity in patients with peripheral T-cell lymphoma (PTCL), including heavily pretreated patients, a new study published online ahead of print in the Journal of Clinical Oncology has shown.

For the study, researchers enrolled 37 patients with histologically confirmed relapsed/refractory PTCL or transformed Mycosis fungoides (tMF). All patients received alisertib 50 mg twice daily for 7 days in 21-day cycles until disease progression or unacceptable toxicity.

Results showed that the overall response rate for patients with PTCL was 30%. In regard to safety, the most common grade and 4 adverse events were neutropenia, anemia, thrombocytopenia, febrile neutropenia, mucositis, and rash.

Continue Reading

There was no association between AAK, Aurora Kinase B, MYC, BCL-2, phosphatidylinositol 3-kinase γ, and Notch 1 expression, and response to alisertib.

RELATED: Hodgkin Lymphoma Outcomes Worse In Medicaid, Uninsured Patients

An international, randomized, phase III trial is currently underway to evaluate alisertib compared with investigator’s choice in patients with PTCL.

According to the Leukemia and Lymphoma Society, T-cell lymphomas account for between 10% and 15% of all non-Hodgkin lymphomas, but they are rare in the United States.


  1. Barr PM, Li H, Spier C, et al. Phase II intergroup trial of alisertib in relapsed and refractory peripheral T-cell lymphoma and transformed mycosis fungoides: SWOG 1108. J Clin Oncol. 2015. [Epub ahead of print]. doi: 10.1200/JCO.2014.60.6327.